07:00 , Oct 13, 2014 |  BC Week In Review  |  Clinical News

18-methoxycoronaridine: Phase I started

Savant said partner Hebron Farmaceutica began a double-blind, placebo-controlled, Brazilian Phase I trial to evaluate oral 18-MC in healthy volunteers. Hebron is developing the compound outside of North America for leishmaniasis under an expanded material...
08:00 , Jan 14, 2013 |  BC Week In Review  |  Company News

Savant HWP, National Institutes of Health neurology, endocrine/metabolic news

Savant HWP received a $6.5 million grant from the NIH's National Institute on Drug Abuse (NIDA) to develop Savant's 18-methoxycoronaridine (18-MC) to treat drug addiction, obesity and other forms of compulsive behavior. 18-MC is a...
08:00 , Dec 24, 2012 |  BioCentury  |  Emerging Company Profile

Savant HWP: Antagonizing addiction

Savant HWP Inc. has developed selective antagonists of the nicotinic acetylcholine receptor alpha(3)beta(4) it believes could treat a wide variety of addiction disorders because the compounds hit a pathway that underlies most pleasure-seeking behaviors, including...